Several studies have indicated that ANO1 may be used as a therapeutic target of tumors because down regulation of ANO1 showed potential therapeutic benefits on HNSCC, ESCC, GIST, breast and prostate cancer [14, 16, 30, 32, 33]. The gene discussed is ANO1; the disease is prostate carcinoma.